Skip to content
Open access

Post-pandemic SARS-CoV-2 infection incidence: a Dutch prospective seroepidemiological cohort study

Oct 2026 · European Journal of Public Health · Vol 36 · 0 citations

Abstract

Abstract   After the acute phase of the COVID-19 pandemic, surveillance was reduced and serological monitoring became crucial to monitor SARS-CoV-2 infections. We estimated infection incidence in the Netherlands during 2023–2024 using repeated serological sampling. We used data from randomly-selected Dutch citizens aged 2-92 years that participated in the nationwide seroepidemiological PIENTER-Corona cohort study. Blood samples were collected thirteen times since April 2020 including four times in the period April 2023–October 2024 and tested for IgG antibodies against Spike-S1 (S1) and Nucleoprotein (N). Infections were identified through anti-N and/or anti-S1 (if not vaccinated) seroconversion or ≥ 4-fold increase, and self-reported positive tests. We estimated the weighted infection incidence (≥1) in 2023–2024 (N = 4261) and total infection count by October 2024 (N = 4574) in the Dutch population, overall and stratified by age, sex, ethnicity, comorbidities and healthcare profession. Between April 2023 and October 2024, the weighted infection incidence was 59.1% [56.8–61.4]; 55.4% was infected once and 3.7% was infected twice or more. Higher infection rates were seen in 30-60 year-olds (ranging 63.3–68.5%), those without comorbidities (62.0%) and those not working in healthcare (62.9%). By October 2024, the median infection count since the start of the pandemic was two; 21.9% had experienced one infection, 50.0% had two and 24.3% had three or more infections. A significant proportion (∼60%) of the Dutch population was infected with SARS-CoV-2 at least once in this 1.5-year post-pandemic period, with incidence varying between sociodemographic groups. These results highlight the importance of serological data to monitor and establish infection incidence in the absence of large-scale testing policies. This information is vital for evaluating disease burden. Key messages • Approximately 60% of the Dutch population experienced at least one SARS-CoV-2 infection in a 1.5 year post-pandemic period between April 2023 and October 2024. • When large-scale testing is unavailable, serological data are crucial for monitoring and establishing infection incidence, and provide essential information for evaluating disease burden.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.